Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.

Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P, French A, Irier H, Choi WB, Easterling K, Yuan H, Wilson LJ, Kotloski R, McNamara JO, Dingledine R, Liotta DC, Traynelis SF, Snyder JP.

J Med Chem. 2008 Sep 25;51(18):5506-21. doi: 10.1021/jm8002153.

2.

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.

Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA.

J Pharmacol Exp Ther. 2002 Sep;302(3):940-8.

3.

Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors.

Tamiz AP, Whittemore ER, Zhou ZL, Huang JC, Drewe JA, Chen JC, Cai SX, Weber E, Woodward RM, Keana JF.

J Med Chem. 1998 Aug 27;41(18):3499-506.

PMID:
9719603
4.

Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor.

Cai SX, Kher SM, Zhou ZL, Ilyin V, Espitia SA, Tran M, Hawkinson JE, Woodward RM, Weber E, Keana JF.

J Med Chem. 1997 Feb 28;40(5):730-8.

PMID:
9057859
5.

Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn.

Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, Sirinathsinghji D, Hill RG, Rupniak NM.

Neuropharmacology. 1999 May;38(5):611-23.

PMID:
10340299
6.

Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists.

Tamiz AP, Cai SX, Zhou ZL, Yuen PW, Schelkun RM, Whittemore ER, Weber E, Woodward RM, Keana JF.

J Med Chem. 1999 Aug 26;42(17):3412-20.

PMID:
10464027
7.

Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (+/-)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype.

Guzikowski AP, Tamiz AP, Acosta-Burruel M, Hong-Bae S, Cai SX, Hawkinson JE, Keana JF, Kesten SR, Shipp CT, Tran M, Whittemore ER, Woodward RM, Wright JL, Zhou ZL.

J Med Chem. 2000 Mar 9;43(5):984-94.

PMID:
10715162
8.

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site.

Cai SX, Zhou ZL, Huang JC, Whittemore ER, Egbuwoku ZO, Lü Y, Hawkinson JE, Woodward RM, Weber E, Keana JF.

J Med Chem. 1996 Aug 16;39(17):3248-55.

PMID:
8765507
9.

Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.

Mosley CA, Myers SJ, Murray EE, Santangelo R, Tahirovic YA, Kurtkaya N, Mullasseril P, Yuan H, Lyuboslavsky P, Le P, Wilson LJ, Yepes M, Dingledine R, Traynelis SF, Liotta DC.

Bioorg Med Chem. 2009 Sep 1;17(17):6463-80. doi: 10.1016/j.bmc.2009.05.085. Epub 2009 Jul 5.

10.
12.

NR2B selective NMDA receptor antagonists.

Nikam SS, Meltzer LT.

Curr Pharm Des. 2002;8(10):845-55. Review.

PMID:
11945135
13.

Antagonists selective for NMDA receptors containing the NR2B subunit.

Chenard BL, Menniti FS.

Curr Pharm Des. 1999 May;5(5):381-404. Review.

PMID:
10213801
14.

A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy.

Löscher W, Lehmann H, Behl B, Seemann D, Teschendorf HJ, Hofmann HP, Lubisch W, Höger T, Lemaire HG, Gross G.

Eur J Neurosci. 1999 Jan;11(1):250-62.

PMID:
9987029
15.

Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid.

Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT.

Br J Pharmacol. 2004 Feb;141(3):508-16. Epub 2004 Jan 12.

17.

Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.

Kleckner NW, Glazewski JC, Chen CC, Moscrip TD.

J Pharmacol Exp Ther. 1999 May;289(2):886-94.

18.

NMDA/NR2B selective antagonists in the treatment of ischemic brain injury.

Wang CX, Shuaib A.

Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):143-51. Review.

PMID:
15857299
19.

4-substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity.

Carling RW, Leeson PD, Moore KW, Moyes CR, Duncton M, Hudson ML, Baker R, Foster AC, Grimwood S, Kemp JA, Marshall GR, Tricklebank MD, Saywell KL.

J Med Chem. 1997 Feb 28;40(5):754-65.

PMID:
9057862
20.

Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors.

Keana JF, Kher SM, Cai SX, Dinsmore CM, Glenn AG, Guastella J, Huang JC, Ilyin V, Lü Y, Mouser PL, et al.

J Med Chem. 1995 Oct 27;38(22):4367-79.

PMID:
7473565

Supplemental Content

Support Center